基于iTRAQ技术的碘难治型甲状腺癌与分化型甲状腺癌的比较蛋白质组学研究

李运洁; 黄鑫; 邓婕; 段东

doi:10.16016/j.1000-5404.201907087

您当前的位置：

首页 >

文章列表页 >

基于iTRAQ技术的碘难治型甲状腺癌与分化型甲状腺癌的比较蛋白质组学研究

基础医学 | 更新时间：2026-01-09

- 基于iTRAQ技术的碘难治型甲状腺癌与分化型甲状腺癌的比较蛋白质组学研究
- Comparative proteomic analysis of differentiated thyroid carcinoma and radioiodine-refractory differentiated thyroid carcinoma based on iTRAQ technique
- 第三军医大学学报 2019年41卷第24期页码：2425-2429
- 作者机构：
  
  400016 重庆，重庆医科大学附属第一医院核医学科
- 作者简介：
  
  [ 段东，E-mail: duandong26@163.com DUAN Dong, E-mail: duandong26@163.com
- 基金信息：
  
  重庆市自然科学基金面上项目(CSTC2019jcyj-msxmX0327)
- DOI：10.16016/j.1000-5404.201907087
  中图分类号： R341;R394.3;R736.1
- 收稿：2019-07-11，
  
  修回：2019-09-15，
  
  纸质出版：2019-12-30
- 稿件说明：
移动端阅览
李运洁, 黄鑫, 邓婕, 等. 基于iTRAQ技术的碘难治型甲状腺癌与分化型甲状腺癌的比较蛋白质组学研究[J]. 第三军医大学学报, 2019,41(24):2425-2429.

Yunjie LI, Xin HUANG, Jie DENG, et al. Comparative proteomic analysis of differentiated thyroid carcinoma and radioiodine-refractory differentiated thyroid carcinoma based on iTRAQ technique[J]. Journal of Third Military Medical University, 2019, 41(24): 2425-2429.
李运洁, 黄鑫, 邓婕, 等. 基于iTRAQ技术的碘难治型甲状腺癌与分化型甲状腺癌的比较蛋白质组学研究[J]. 第三军医大学学报, 2019,41(24):2425-2429. DOI： 10.16016/j.1000-5404.201907087.

Yunjie LI, Xin HUANG, Jie DENG, et al. Comparative proteomic analysis of differentiated thyroid carcinoma and radioiodine-refractory differentiated thyroid carcinoma based on iTRAQ technique[J]. Journal of Third Military Medical University, 2019, 41(24): 2425-2429. DOI： 10.16016/j.1000-5404.201907087.

摘要

目的

寻找碘难治型甲状腺癌和分化型甲状腺癌之间的差异蛋白，探讨碘难治型甲状腺癌发生的机制，探索可能的核素分子治疗靶点。

方法

收集2018年6月至2019年3月本科收治的碘难治型甲状腺癌和分化型甲状腺癌患者颈部转移淋巴结各3例，利用iTRAQ技术联合质谱分析得到差异蛋白，并通过生物信息学方法对差异蛋白进行GO功能注释、KEGG通路分析，并利用TCGA、TCPA数据库对部分差异蛋白进行验证。

结果

鉴定得到的差异蛋白共665个，其中显著上调的蛋白327个，显著下调的蛋白338个。ECM1、CHI3L1、LAMA5、14-3-3 eta、CDC42、RAC2、MYL9等差异蛋白广泛参与肿瘤血管生成、侵袭转移及细胞失分化过程。同时，差异蛋白富集于包括代谢通路、黏着斑及其他多条信号通路。

结论

碘难治型甲状腺癌和分化型甲状腺癌的差异蛋白较多，其主要功能涉及调节转运体活性及酶活性等，参与细胞代谢等多个生物过程。ECM1、CHI3L1及CDC42通过与MAPK通路中部分蛋白相互作用促进肿瘤发展，可能成为核素治疗的潜在靶点。

Abstract

Objective

To identify the differentially expressed proteins between differentiated thyroid carcinoma and radioiodine-refractory differentiated thyroid carcinoma

explore the pathogenetic mechanism of radioiodine-refractory differentiated thyroid carcinoma

and identify potential targets for nuclide molecular therapy.

Methods

We collected the samples of metastatic lymph nodes from 3 patients with radioiodine-refractory differentiated thyroid carcinoma and 3 patients with differentiated thyroid carcinoma treated in our department between June

2018 and March

2019. The differential proteins were detected using iTRAQ technique coupled with mass spectrometry. The raw data of iTRAQ were analyzed with a bioinformatic approach for annotating the function of the differential proteins using GO database and analyzing the interaction of the proteins in KEGG signaling pathways. Some of the differential proteins were verified by analysis of TCGA and TCPA databases.

Results

We identified a total of 665 differential proteins between the 2 cancers

including 327 significantly up-regulated proteins and 338 down-regulated proteins. The differential proteins

including ECM1

CHI3L1

LAMA5

14-3-3 eta

CDC42

RAC2

and MYL9

participated in the regulation of tumor angiogenesis

invasion

metastasis

and cell dedifferentiation. The differential proteins were significantly enriched in multiple signaling pathways involved in cell metabolism

focal adhesion

and other cell processes.

Conclusion

Many proteins are differentially expressed between differentiated thyroid carcinoma and radioiodine-refractory differentiated thyroid carcinoma. These proteins are involved in the regulation of the activity of transporters and enzymes and participate in multiple biological processes. Among these differential proteins

ECM1

CHI3L1

and CDC42 promote tumor progression by interacting with the proteins in the MAPK signaling pathway

and may serve as potential targets for radionuclide therapy.

关键词

Keywords

references

LIM H, DEVESA S S, SOSA J A, et al . Trends in thyroid cancer incidence and mortality in the United States, 1974-2013[J ] . JAMA, 2017, 317(13): 1338-1348. DOI:10.1001/jama.2017.2719.

KLAIN M, PACE L, ZAMPELLA E, et al . Outcome of patients with differentiated thyroid cancer treated with 131-iodine on the basis of a detectable serum thyroglobulin level after initial treatment[J ] . Front Endocrinol (Lausanne), 2019, 10: 146. DOI:10.3389/fendo.2019.00146.

YU S T, GE J N, LUO J Y, et al . Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis[J ] . Cancer Manag Res, 2019, 11: 1525-1532. DOI:10.2147/CMAR.S191499.

SUZUKI C, KIYOTA N, IMAMURA Y, et al . Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer[J ] . Head Neck, 2019, 41(9): 3023-3032. DOI:10.1002/hed.25784.

张文文, 郝珊瑚, 王治国, 等. 125 I粒子植入治疗 131 I难治性分化型甲状腺癌淋巴结转移的临床价值[J ] .中华核医学与分子影像杂志, 2018, 38(1): 9-13..

ZHANG W W, HAO S H, WANG Z G, et al . Clinical value of 125 I seeds implantation in treatment of lymph nodes metastases from 131 I refractory differentiated thyroid carcinoma[J ] . Chin J Nucl Med Mol Imaging, 2018, 38(1): 9-13. DOI: 10.3760/cma.j.issn.2095-2848.2018.01.003..

KREISSL M C, JANSSEN M J R, NAGARAJAH J. Current treatment strategies in metastasized differentiated thyroidcancer[J]. J Nucl Med, 2019, 60(1): 9-15. DOI: 10.2967/jnumed.117.190819.

张墨, 陈骊珠, 杨泽宇, 等.基于iTRAQ蛋白质组学技术对前列腺癌血清标志物的筛查[J].现代肿瘤医学, 2018, 26(1): 18-21.

ZHANG M, CHEN L Z, YANG Z Y, et al . Screening study for prostate cancer serum biomarkers based on iTRAQ proteomic technology[J ] . J Mod Oncol, 2018, 26(1): 18-21.

CHAERKADY R, HARSHA H C, NALLI A, et al . Aquantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma[J ] . J Proteome Res, 2008, 7(10): 4289-4298. DOI: 10.1021/pr800197z.

WEITZMAN S P, SHERMAN S I. Novel drug treatments of progressive radioiodine-refractory differentiated thyroidcancer[J]. Endocrinol Metab Clin North Am, 2019, 48(1): 253-268. DOI: 10.1016/j.ecl.2018.10.009.

WÄCHTER S, WUNDERLICH A, GREENE B, et al .Selumetinib activity in thyroid cancer cells: modulation of sodium iodide symporter and associated miRNAs[J ] . Int J Mol Sci, 2018, 19(7): 2077. DOI:10.3390/ijms19072077.

武元元, 王军.甲状腺未分化癌的靶向药物治疗进展[J].国际肿瘤学杂志, 2019, 46(2): 98-101.

WU Y Y, WANG J. Advancement of targeted agents in the treatment of anaplastic thyroid carcinoma[J]. J Int Oncol, 2019, 46(2): 98-101. DOI: 10.3760/cma.j.issn.1673-422X.2019.02.008.

BERDELOU A, LAMARTINA L, KLAIN M, et al . Treatment of refractory thyroidcancer[J ] . Endocr Relat Cancer, 2018, 25(4): R209-R223. DOI: 10.1530/ERC-17-0542.

NAOUM G E, MORKOS M, KIM B, et al . Novel targeted therapies and immunotherapy for advanced thyroidcancers[J ] . Mol Cancer, 2018, 17(1): 51. DOI: 10.1186/s12943-018-0786-0.

SHIN E, KOO J S. Expression of proteins related toautotaxin-lysophosphatidate signaling in thyroid tumors[J]. J Transl Med, 2019, 17(1): 288. DOI: 10.1186/s12967-019-2028-7.

GALUPPINI F, VIANELLO F, CENSI S, et al . Differentiated thyroid carcinoma in pediatric age: genetic and clinicalscenario[J ] . Front Endocrinol(Lausanne), 2019, 10: 552. DOI: 10.3389/fendo.2019.00552.

DE MORAIS R M, SOBRINHO A B, DE SOUZA SILVA C M, et al . The role of the NIS (SLC5A5) gene in papillary thyroid cancer: A systematic review[J ] . Int J Endocrinol, 2018, 2018: 1-11. DOI: 10.1155/2018/9128754.

CHENG L X, LIU M, RUAN M M, et al . Challenges and strategies on radioiodine treatment for differentiated thyroid carcinoma[J ] . Hell J Nucl Med, 2016, 19(1): 23-32. DOI: 10.1967/s002449910334.

SON S H, GANGADARAN P, AHN B C. A novel strategy of transferring NIS protein to cells using extracellular vesicles leads to increase in iodine uptake andcytotoxicity[J]. Int J Nanomed, 2019, 14: 1779-1787. DOI: 10.2147/IJN.S189738.

ZHANG K, LIU J Q, LI C L, et al . Identification and validation of potential target ge nes in papillary thyroid cancer[J ] . Eur J Pharmacol, 2019, 843: 217-225. DOI: 10.1016/j.ejphar.2018.11.026.

CHI J S, XIA X J, ZHANG L F, et al . Helicobacter pylori induces GATA3-dependentchitinase 3 like 1 (CHI3L1) upregulation and contributes to vascular endothelial injuries[J ] . Med Sci Monit, 2019, 25: 4837-4848. DOI: 10.12659/MSM.916311.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

应用iTRAQ技术筛选儿童皮质发育障碍性癫痫差异表达蛋白

双向电泳结合质谱法分析双相情感障碍患者血浆差异表达蛋白

利用2DE-MS技术筛选和鉴定大肠癌血清标志物

鱼藤酮和MPTP慢性帕金森病小鼠黑质共同差异蛋白研究

正常与脑缺血大鼠脑皮质线粒体的比较蛋白质组学研究